Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 4/20 | 0.46 |
| ▸ | FEN1 | P39748 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4689570 | 0.88 | ALDH1A1 (0.56) | L3MBTL1KDM4EMAPK1PARP1LMNA | |
| SCHEMBL29444425 | 0.88 | ALDH1A1 (0.56) | L3MBTL1KDM4EMAPK1PARP1LMNA | |
| SCHEMBL13918097 | 0.83 | L3MBTL1 (0.53) | L3MBTL1KDM4EMAPK1PARP1LMNA | |
| SCHEMBL30758864 | 0.82 | PARP1 (0.61) | L3MBTL1KDM4EMAPK1PARP1LMNA | |
| SCHEMBL11269818 | 0.82 | KDM4E (0.50) | KDM4EPARP1ERCC5FEN1NPC1 | |
| SCHEMBL2263377 | 0.82 | CTNNB1 (0.54) | KDM4EPARP1LMNAHPGDERCC5 | |
| SCHEMBL25516644 | 0.82 | RXFP1 (0.45) | L3MBTL1KDM4EMAPK1PARP1LMNA | |
| SCHEMBL20487359 | 0.81 | KDM4E (0.54) | L3MBTL1KDM4EPARP1LMNAHPGD | |
| SCHEMBL20239513 | 0.81 | KMT2A (0.61) | KDM4EPARP1ERCC5FEN1NPC1 | |
| SCHEMBL8231217 | 0.81 | ERCC5 (0.69) | L3MBTL1KDM4EPARP1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667629-B2 | Isoxazole derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-20220081433-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3730491-A1 | ISOXAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-7169797-B2 | Protein-tyrosine phosphatase inhibitors and uses thereof | ABBOTT LABORATORIES (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040214870-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid | ABBVIE INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | ABBOTT LABORATORIES | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667629-B2 | Isoxazole derivative, preparation method therefor, and use thereof | CYP4A11, CYP4F11, SLC10A1 | L3MBTL1 4810/4885KDM4E 4612/4885MAPK1 1620/4885 |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | L3MBTL1 4149/4885KDM4E 3694/4885MAPK1 868/4885 |
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | G6PC1, PPP1R1B, PPP1R7 | L3MBTL1 2516/4885KDM4E 1855/4885MAPK1 339/4885 |
| US-20220081433-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, SMC1A | L3MBTL1 4368/4885KDM4E 3213/4885MAPK1 4034/4885 |
| US-20040214870-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid | G6PC1, PPP1R7, PPP1R1B | L3MBTL1 2715/4885KDM4E 768/4885MAPK1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.